Moore Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Moore Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$773K	Hold	105,000	–	–	0.01%	508
2026 Q1	$1.33M	Hold	105,000	–	–	0.03%	342
2025 Q4	$1.08M	Hold	105,000	–	–	0.02%	441
2025 Q3	$609K	Hold	105,000	–	–	0.01%	470
2025 Q2	$706K	Hold	105,000	–	–	0.01%	405
2025 Q1	$949K	Hold	105,000	–	–	0.02%	322
2024 Q4	$1.82M	Hold	105,000	–	–	0.02%	336
2024 Q3	$1.68M	Hold	105,000	–	–	0.03%	319
2024 Q2	$1.5M	Hold	105,000	–	–	0.03%	287
2024 Q1	$1.49M	Hold	105,000	–	–	0.02%	284
2023 Q4	$1.58M	Hold	105,000	–	–	0.03%	247
2023 Q3	$1.66M	Hold	105,000	–	–	0.03%	263
2023 Q2	$1.59M	Hold	105,000	–	–	0.03%	270
2023 Q1	$1.52M	Hold	105,000	–	–	0.03%	264
2022 Q4	$1.42M	Hold	105,000	–	–	0.03%	308
2022 Q3	$1.66M	Hold	105,000	–	–	0.04%	377
2022 Q2	$1.28M	Hold	105,000	–	–	0.03%	378
2022 Q1	$986K	Hold	105,000	–	–	0.03%	424
2021 Q4	$1.8M	Buy	+105,000	New	+$2.55M	0.04%	414

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Moore Capital Management's TRDA Position: Q2 2026 in Review

Moore Capital Management held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 105,000 shares worth $773K. The position accounts for 0.01% of the portfolio, ranked #508.

Moore Capital Management first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.82M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Moore Capital Management held 105,000 shares of Entrada Therapeutics worth $773K as of Q2 2026.
Moore Capital Management left its Entrada Therapeutics share count unchanged in Q2 2026.
Entrada Therapeutics made up 0.01% of Moore Capital Management's portfolio in Q2 2026, its #508 holding.
Moore Capital Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
Moore Capital Management's Entrada Therapeutics position peaked at $1.82M in Q4 2024.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.